AstraZeneca addresses report that CEO Pascal Soriot plans to depart

AstraZeneca brushed off a news report that longtime CEO Pascal Soriot plans to leave the company.

British tabloid The Daily Mail on Sunday had reported that the 64-year-old chief may depart as soon as next year, citing an unnamed source. AstraZeneca’s stock was down more than 2% on Monday afternoon, trading at about $67 per share.

An AstraZeneca spokesperson told Endpoints News via email that the company doesn’t “comment on market rumors.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Reproductive impact of changes in the vaginal microbiome of obese women

Study explores the impact of obesity on vaginal microbiota and reproduction.

July 5, 2023

My four kids and I all have ADHD. We need telehealth options

On Thursday, the CDC released new data showing that almost 15.5 million U.S. adults are living with ADHD. More than half of those individuals received

October 10, 2024

COVID-19’s lasting impact on smell and brain health unveiled

Study reviews the impact of COVID-19 on olfactory dysfunction and its link to neurocognitive disorders, highlighting MRI findings and potential treatments for smell loss.

February 13, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.